San Diego-based mostly Viking Therapeutics marked itself as a significant competitor from the weight loss drug industry in February following revealing promising data from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection and in March the co